Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qi-Zhi-Tong-Luo Capsule (also known as Qizhitongluo Capsule) is a traditional Chinese medicine (TCM) formulation developed by the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, and Shanxi Zhendong Pharmaceutical. It is formulated to promote blood circulation, resolve phlegm, and address Qi deficiency and blood stasis/phlegm obstruction. The capsule is approved in China for the auxiliary treatment of stroke recovery-stage sequelae, including hemiplegia, limb numbness, facial paralysis, language difficulties, and fatigue. It is also under clinical evaluation for the treatment of vascular cognitive impairment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qi-Zhi-Tong-Luo Capsule.